Showing 6971-6980 of 9760 results for "".
- Three Dermal Filler Patients Had Adverse Reactions to the Moderna COVID-19 Vaccinehttps://practicaldermatology.com/news/three-filler-patients-had-adverse-reactions-to-the-moderna-covid-19-vaccine/2460642/Three patients with dermal fillers have had adverse reactions to the Moderna COVID-19 vaccine, according to the Aesthetic Society. The FDA intends to note this in its prescribing information. There have been no reported cases in patients receiving the Pfizer COVID-19 vaccine.
- For Upper Facial Lines, DaxibotulinumtoxinA Succeeds in Phase 2https://practicaldermatology.com/news/for-upper-facial-lines-daxibotulinumtoxina-succeeds-in-phase-2/2460637/Topline efficacy and safety results from the phase 2 multicenter, open-label study of Revance's investigational drug candidate DaxibotulinumtoxinA for Injection for the combined treatment of upper facial lines, show high levels of patient satisfaction. The 36-week study enrolled 48
- Breaking News: AbbVie’s Allergan Wins Trade Secret Case Against Evolushttps://practicaldermatology.com/news/breaking-news-abbvies-allergan-wins-trade-secret-case-against-evolus/2460635/AbbVie Inc.’s Allergan won a U.S. trade agency order to block Evolus Inc. and its partner Daewoong Pharmaceutical Co. from importing Jeuveau into the U.S. for 21 months, according to media reports. The U.S. International Trade Commission upheld a judge’s findings that Jeuvea
- Hydrafacial To Go Public After $1.1 Billion Dealhttps://practicaldermatology.com/news/hydrafacial-to-go-public-after-11-billion-deal/2460634/The HydraFacialCompany and Vesper Healthcare, a special purpose acquisition company (SPAC) co-founded by Brent Saunders, former CEO of Allergan, have entered into a definitive merger agreement. Under the terms of the agreement, HydraFacial and Vesper Healthcare will combine, and HydraFa
- Evelo's AD Candidate Meets Phase 1b Endpointshttps://practicaldermatology.com/news/evelos-ad-candidate-meets-phase-1b-endpoints/2460631/Evelo Biosciences, Inc.’s investigational atopic dermatitis treatment EDP1815 was well tolerated with no serious adverse events in a phase 1b clinical trial. According to the company, the oral drug candidate studied in 23 evaluable subjects with
- Olay Body Teams Up with Olympic Snowboarder Jamie Anderson to Reduce Winter Skin Drynesshttps://practicaldermatology.com/news/olay-body-teams-up-with-olympic-snowboarder-jamie-anderson-to-reduce-winter-skin-dryness/2460626/Olay Body is teaming up with professional snowboarder and 2X Olympic gold medalist, Jamie Anderson, to give women the tools they need to combat the snow and freezing temperatures that take a toll on skin. Olay Body also joined forces with Oro Valley, Ariz-based dermatologist Sheil
- Dupixent Approved by European Commission as First and Only Biologic Medicine for Children Aged 6 to 11 Years with Severe ADhttps://practicaldermatology.com/news/dupixent-approved-by-european-commission-as-first-and-only-biologic-medicine-for-children-aged-6-to-11-years-with-severe-ad/2460619/The European Commission (EC) has given its nod to Dupixent (dupilumab) for children 6 to 11 with severe atopic dermatitis who are candidates for systemic therapy. Dupixent is the only systemic medicine approved in the EU to treat these patients. "As the parent
- Actress Zosia Mamet Named New Face of Isdinhttps://practicaldermatology.com/news/actress-zosia-mamet-is-the-new-face-of-isdin/2460617/Zosia Mamet, star of the upcoming HBO Max series The Flight Attendant, is ISDIN’s newest ambassador. Currently, Zosia is using Isdin’s Micellar Solution to cleanse her skin every morning and evening before bed. After cleansing in the morning, she applies Flavo-C U
- Crown Aesthetics Scores Class IIa CE Certification for SkinPen Precision from British Standards Institutionhttps://practicaldermatology.com/news/crown-aesthetics-scores-class-iia-ce-certification-for-skinpen-precision/2460614/The British Standards Institution (BSI) granted a Class IIa CE Certification mark to Crown Aesthetics’ SkinPen Precision. The certification confirms SkinPen as a treatment to improve the appearance of facial acne scars in adults aged 22 years or older and to improve the appe
- Avita Therapeutics, Houston Methodist Research Institute to Develop New Ways to Rejuvenate Aging Skinhttps://practicaldermatology.com/news/avita-therapeutics-houston-methodist-research-institute-to-develop-new-ways-to-rejuvenate-aging-skin/2460608/Avita Therapeutics’ is partnering with Houston Methodist Research Institute (HMRI) to identify novel approaches to reverse skin aging and rejuvenate skin with the potential for broader applicability such as scar revision and wound healing. The project seeks to establish